Dizal Pharmaceutical Co., Ltd (SHA: 688192), a biopharmaceutical company based in China, has presented updates on the WU-KONG series study for its next-generation epidermal growth factor receptor (EGFR) inhibitor, sunvozertinib (DZD9008), at the 2024 European Society of Medical Oncology (ESMO) Congress.
Sunvozertinib received approval in China in August of the previous year for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR Exon20ins mutation in patients who have been previously treated with platinum chemotherapy or are intolerant to platinum.
The WU-KONG1B study, updated at ESMO 2024, enrolled a total of 107 patients, covering at least 33 subtypes of EGFR exon 20 insertion mutations (Exon20ins). As of March 22, 2024, global subgroup data indicated that 92.4% of patients experienced a reduction in target lesion size according to the Independent Review Committee (IRC) assessment. The optimal objective response rate (ORR) evaluated by IRC was 53.3%, with 3 cases achieving a complete response (CR). Sunvozertinib demonstrated potent and durable anti-tumor efficacy and favorable safety in the treatment of EGFR Exon20ins NSCLC, irrespective of patient mutation subtype, ethnicity, region, baseline brain metastasis, or prior treatment with Amivantamab or immunotherapy, making the research findings globally representative.
Additionally, the Phase III WU-KONG28 study of sunvozertinib is progressing in comparison with chemotherapy for first-line EGFR Exon20ins NSCLC across America, Europe, and Asia. – Flcube.com
